U.S. Healthtech Stock News

Simmons First National recently reported quarterly revenue of US$236.3 million, a 12.7% year-on-year increase that surpassed analyst expectations by 1.2%, although earnings per share only matched forecasts and tangible book value per share fell short. This mix of strong top-line momentum and softer profitability metrics highlights how the bank is capturing higher revenues while still contending with margin and balance-sheet pressures common across regional lenders. We’ll now examine how this...

In December 2025, United Rentals announced it had rolled out Manual Assist AI across its operations, a web-based tool built with Amazon Web Services that gives more than 4,000 monthly users AI-powered access to thousands of equipment manuals and diagnostics. This enterprise-wide AI adoption highlights how United Rentals is using cloud-based generative tools to speed repairs, reduce downtime, and keep more rental equipment productive on customer jobsites. Next, we’ll explore how this...

The FDA approval of MYQORZO for obstructive hypertrophic cardiomyopathy has initiated Royalty Pharma (RPRX)'s royalty stream and repayment terms, a material catalyst that strengthens its long-term cash flow profile. See our latest analysis for Royalty Pharma. This latest FDA milestone lands on top of a strong run, with the share price up 50.68 percent year to date and a 12 month total shareholder return of 57.78 percent. This suggests momentum is building as investors reassess Royalty...

Equinix (EQIX) is back on traders' screens after fresh earnings revisions and a friendlier rate backdrop pushed data center REITs higher, tying its story even closer to the AI infrastructure build out. See our latest analysis for Equinix. Despite the upbeat earnings revisions and AI driven tailwinds, Equinix’s share price return has stayed under pressure with a roughly 19.7 percent year to date decline, even though its three year total shareholder return of about 22.7 percent still signals...

In recent days, OceanFirst Financial has attracted increased attention after DA Davidson, Keefe, Bruyette & Woods, and Raymond James all raised their ratings on the bank to more positive levels. This rare clustering of upgrades from multiple research houses highlights a growing conviction in OceanFirst’s business trajectory and risk profile among professional analysts. We’ll now examine how this wave of analyst upgrades might reshape OceanFirst Financial’s investment narrative, especially...

Plains All American Pipeline has moved to safeguard its payout by selling its Canadian natural gas liquids assets for US$3.80 billion and acquiring the Epic Crude Oil Pipeline, aiming for about 85% of earnings from more stable sources and a leverage ratio around the midpoint of its 3.5 times target range. This reshaping of the portfolio, combined with a comfortably covered high-yield payout and an ambition for roughly 10% annual dividend growth until reaching its target coverage, signals a...

Distribution Solutions Group (DSGR) just secured a larger, extended credit facility running through 2030, increasing both its term debt and revolving credit, and effectively giving management more flexibility to fund future growth initiatives. See our latest analysis for Distribution Solutions Group. Even with the expanded credit facility hinting at bolder growth plans, the stock has been under pressure, with a weak year to date share price return but still a solid three year total...

Keurig Dr Pepper (KDP) has been grinding out steady growth, but the stock’s recent slip this year contrasts with improving revenue and net income trends, raising fresh questions about how investors are valuing its long term cash generation. See our latest analysis for Keurig Dr Pepper. At around $28.24, Keurig Dr Pepper’s recent share price return has been weak year to date, but the 90 day share price return of 7.58 percent hints that sentiment toward its cash generation story may be...

Flowserve Corporation ( NYSE:FLS ) stock is about to trade ex-dividend in 2 days. The ex-dividend date occurs one day...

Avis Budget Group recently reported that it has not increased available rental days over the past two years, while its return on invested capital has fallen and debt-fueled cash burn has intensified, raising fresh concern about demand and capital efficiency. Taken together, these trends point to a business struggling to find profitable growth opportunities in a potentially saturated market, with balance sheet pressure heightening the risk profile for investors. We’ll now examine how Avis...

How Quest Diagnostics Stock Has Been Performing Quest Diagnostics (DGX) has quietly outpaced many healthcare peers over the past year, with the stock up about 17% and a solid 64% gain over the past 5 years. That kind of long term compounding, backed by steady revenue and net income growth, makes Quest interesting for investors who prefer durable cash flows rather than story driven momentum. See our latest analysis for Quest Diagnostics. In the near term, the 1 month share price return of...

Paychex (PAYX) just checked several important boxes at once, with Q2 revenue jumping in the high teens, the Paycor acquisition pulling its weight, and management lifting its adjusted EPS growth outlook for fiscal 2026. See our latest analysis for Paychex. Even with today’s jump to a share price of $114.88 and a 1 month share price return of 3.07%, Paychex is still working off a softer patch. The year to date share price return of minus 17.05% and a 1 year total shareholder return of minus...

TriCo Bancshares recently saw its stock price move above its 200-day moving average, alongside a past quarterly dividend announcement payable on December 19th and a series of updated analyst ratings. The combination of these analyst upgrades and the confirmed cash return to shareholders has sharpened investor attention on how TriCo balances growth and income. We’ll now examine how the recent analyst upgrades shape TriCo Bancshares’ investment narrative and what they could mean for...

Earlier this month, Charles Schwab announced a wave of enhancements across Schwab.com, Schwab Mobile, and thinkorswim, adding richer research tools, more flexible options trading workflows, portfolio tax-lot controls, and new futures contracts including 1 OZ Gold and Solana products to better serve its increasingly active retail traders. The upgrades, paired with Schwab’s expanding branch support network and focus on a comprehensive trading ecosystem, underline how the firm is using...

Mobileye Global (MBLY) is back on traders radar after Ruter and Holo said they will team up with Volkswagens MOIA to deploy ID. Buzz AD shuttles using Mobileye Drive in Oslo from 2026. See our latest analysis for Mobileye Global. Despite this high profile Oslo deployment adding to wins with MOIA, Uber and German transit operators, Mobileye Global's share price return has been weak this year, signalling that investors are still cautious even as long term autonomous driving potential builds. If...

In December 2025, Phillips 66 filed a US$1.72 billion shelf registration to offer 13,000,000 common shares for an ESOP-related transaction, while also announcing with Kinder Morgan that the Western Gateway Pipeline’s initial open season had closed following strong shipper interest. The planned second open season in January 2026 for remaining Western Gateway capacity, including new destinations west of Colton, California, underscores Phillips 66’s push to strengthen its refined products...

Akamai Technologies has launched ISV Catalyst, a new partner program aimed at accelerating growth for independent software vendors (ISVs) on its globally distributed cloud platform. This initiative is designed to support ISVs in creating, marketing, and selling cloud-native solutions, particularly those involving artificial intelligence and multicloud capabilities. By offering no referral fees for ISVs during the first year and various promotional opportunities, the program aims to lower...

Despite an already strong run, HUHUTECH International Group Inc. ( NASDAQ:HUHU ) shares have been powering on, with a...

In December 2025, Wasatch BioLabs announced a co-marketing agreement with Agilent Technologies to pair Agilent’s SureSelect and Avida enrichment chemistries with WBL’s Oxford Nanopore-based Direct Targeted Methylation Sequencing platform, enabling precise, custom native-read targeting of genomic and cell-free DNA for research and clinical applications. The collaboration aims to broaden access to scalable, cost-efficient native-read multi-omic assays, especially for liquid biopsy, oncology,...

In December 2025, MarketAxess Holdings Inc. announced a new share repurchase program authorizing the buyback of up to US$400 million of its stock, signaling a major capital allocation move by the electronic bond-trading platform. This buyback plan highlights management’s confidence in the company’s long-term cash generation and may amplify the impact of any future earnings growth on each remaining share. Next, we’ll assess how MarketAxess’s US$400 million buyback authorization could reshape...

Wetouch Technology Inc. ( NASDAQ:WETH ) shares have retraced a considerable 26% in the last month, reversing a fair...

If you are wondering whether Alibaba Group Holding is still a bargain after its big rebound, or if you have already missed the boat, you are in the right place to unpack what the current price really implies. The stock has climbed 77.7% year to date and 80.3% over the last year, even though the 5 year return is still down 28.6%. This combination points to shifting market expectations and a possible rerating story in progress. Much of this renewed interest has been driven by Beijing easing...

MGIC Investment (MTG) has been getting fresh attention after its latest earnings beat on earnings per share, even though revenue landed just shy of forecasts, and that combination is reshaping how investors view the stock. See our latest analysis for MGIC Investment. That upbeat earnings reaction has fed into a steady uptrend, with the share price at $29.66 and a roughly 25 percent year to date share price return. The three year total shareholder return of about 146 percent shows that...

In recent years, IDEX’s organic revenue growth has trailed sector benchmarks, while earnings per share have fallen even as overall revenue increased. This combination of weaker organic momentum, less profitable incremental sales, and diminishing returns on capital raises questions about the durability of IDEX’s profit engine. We’ll now explore how weakening organic growth and declining earnings efficiency may affect IDEX’s previously growth-focused investment narrative. The end of cancer?...